Merck (MRK) Share-based Compensation (2009 - 2026)

Merck has disclosed Share-based Compensation across 18 years of filings, most recently posting $185.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 5.13% year-over-year to $185.0 million; the TTM figure through Mar 2026 stood at $810.0 million (up 3.85% YoY), while the FY2025 annual figure was $820.0 million, up 7.75% from the prior year.
• Share-based Compensation fell to $185.0 million in Q1 2026, from $205.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for MRK reached as high as $216.0 million in Q2 2025 and fell as low as $120.0 million in Q1 2022.
• The 5-year median for Share-based Compensation is $176.0 million (2024), against an average of $173.6 million.
• Annual changes were most pronounced in 2023 — Share-based Compensation climbed 23.36% — and 2026, when it decreased 5.13%.
• A 5-year view of Share-based Compensation shows it stood at $145.0 million in 2022, then gained by 15.17% to $167.0 million in 2023, then increased by 11.98% to $187.0 million in 2024, then grew by 9.63% to $205.0 million in 2025, then declined by 9.76% to $185.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $185.0 million, $205.0 million, and $204.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.